Connect with us

Technology

HistoIndex to Present Latest Findings on AI-based Analysis using Stain-free Digital Pathology with 12 Accepted Abstracts at AASLD The Liver Meeting® 2024

Published

on

SINGAPORE, Nov. 9, 2024 /PRNewswire/ — HistoIndex, a pioneering leader in artificial intelligence (AI) and stain-free digital pathology, will present its latest research findings and advancements in AI-based analysis at the 75th The Liver Meeting® (TLM) 2024, hosted by the American Association for the Study of Liver Diseases (AASLD). The conference, which brings together leading scientists, clinicians, and industry experts in hepatology, will be held from November 15th to 19th, in San Diego, California.

HistoIndex’s team, including the KOLs involved in the studies, will be sharing insights into the company’s innovative approach to assess regression and progression of liver fibrosis, including groundbreaking AI-enabled methodology that enhance the detection, quantification, and assessment of various liver conditions such as Metabolic Dysfunction-Associated Steatohepatitis (MASH) and fibrosis. With the incidence of liver diseases rising globally, these presentations are timely in showcasing how HistoIndex’s stain-free digital pathology solutions and AI technology address current challenges by providing highly accurate, reproducible, and interpretable data from liver biopsies.

As a leader in AI-based analysis using stain-free digital pathology, we are honored to have extensive representation at TLM 2024, showcasing twelve abstracts from phase 2b and phase 3 clinical trials that span four distinct mechanisms of action (MOA) in MASH. Commenting on the significance of the accepted abstracts, Dr. Dean Tai, Chief Scientific Officer at HistoIndex stated, “These findings from the four distinct MOA phase 2b/3 MASH trials, along with diverse studies highlighting the utility of our technology in cirrhotic MASH, differentiating pediatric and adult MASH, predicting clinical outcomes, and understanding hepatocellular carcinoma recurrence in chronic hepatitis B patients, underscore the transformative role of AI in advancing liver disease diagnosis, prognosis and personalized treatment. We are excited to share these advancements and their impact on clinical trials leading to routine clinical care.”

Key Highlights from HistoIndex at TLM 2024

The HistoIndex team will be involved in multiple oral and poster sessions, highlighting its commitment to advancing liver research and supporting the global hepatology community:

Oral Presentation | Sunday, November 17th, 2.45pm – 3pm
Title: AI-based digital pathology shows that denifanstat improves multiple parameters of fibrosis and reduces progression to cirrhosis in MASH patients with F2/F3 fibrosis – results of the FASCINATE-2 study
Presenter: Dr. Mary Rinella
Publication Number: 170

Poster Presentations

Poster Session I | Friday, November 15th, 1:00 PM2:00 PM

Title: Application of artificial intelligence algorithm as a vascular evaluation tool for intra-stage assessment in the cirrhotic patients with metabolic dysfunction-associated steatotic liver disease
Presenter: Dr Zhengxin Li
Publication Number: 1561

Title: The role of steatosis and fibrosis parameters in predicting hepatocellular carcinoma recurrence in chronic hepatitis B patients
Presenter: Dr Ke Yin
Publication Number: 1275

Poster Session II | Saturday, November 16th, 1:00 PM2:00 PM

Title: Comparative evaluation of zonal fibrosis patterns in pediatric and adult metabolic dysfunction-associated steatohepatitis biopsies using Second Harmonic Generation/Two Photon Excitation-based qFibrosis analysis.
Presenter: Dr Naim Alkhouri
Publication Number: TBC

Title: Evaluating impact of weight changes on histological patterns of liver fibrosis in MASH: implications for spatial interrogation
Presenter: Dr Kutbuddin Akbary
Publication Number: 2114

Title: Evaluation of the consistency and heterogeneity of adjacent sections in fibrosis assessment using AI-based qFibrosis in virtual liver needle biopsies
Presenter: Dr Yayun Ren
Publication Number: 2047

Title: Independent validation of second harmonic generation/two photon excitation imaging and artificial intelligence-based SNOF index for metabolic dysfunction associated steatohepatitis cirrhosis assessment
Presenter: Dr Kutbuddin Akbary
Publication Number: 2065

Title: Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution and histological injury allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease
Presenter: Dr Jonathan Fallowfield
Publication Number: 2080

Poster Session III | Sunday, November 17th, 1:00 PM2:00 PM

Title: Fibrosis regression after Tirzepatide treatment of non-cirrhotic MASH for 52 weeks occurs in a zone-dependent manner
Presenter: Dr Arun Sanyal
Publication Number: 3202

Title: Validating pre-identified morphological baseline features for predicting fibrosis progression in MAESTRO-NASH
Presenter: Dr Jörn Schattenberg
Publication Number: 3184

Poster Session: Late Breaking Posters | Monday, November 18th: 8:00 AM5:00 PM

Title: AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with Efruxifermin treatment of patients with F2-F3 MASH in the HARMONY study
Presenter: Dr Mazen Noureddin
Publication Number: 5047

Title: Efruxifermin significantly reduced proportion of subjects with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study
Presenter: Dr Mazen Noureddin
Publication Number: 5021

Breakfast Meeting: Bridging Clinical Research and Clinical Care

In addition to the scientific sessions, HistoIndex will be hosting a breakfast meeting on November 15th, offering a unique opportunity for clinicians, researchers, and industry partners to interact with the HistoIndex team and KOLs on the transformative potential of AI-based analysis using stain-free digital pathology in current MASH clinical trials and its role in the routine clinical care of MASH patients post drug approvals. If you are keen, please register here today at https://forms.gle/2gBJ6mvSeadHHBNi6.

Visit HistoIndex at Booth #1225

All attendees of TLM 2024 are invited to visit the HistoIndex exhibition booth #1225 and experience the company’s Second Harmonic Generation (SHG) technology and AI-enabled analytics with hands-on interactive demonstrations. The exhibition booth will be staffed by knowledgeable company representatives eager to engage with attendees and discuss potential partnerships.

For more information about HistoIndex’s participation in TLM 2024, please visit www.histoindex.com.

About HistoIndex

Founded in 2010, HistoIndex pioneers in stain-free, fully automated imaging solutions for visualizing and quantifying fibrosis in biological tissues. By combining cutting-edge biophotonic technology with AI-based analysis, HistoIndex provides innovative tools to improve the assessment of fibrosis changes and drug efficacy. The Company’s breakthrough digital pathology solutions are accelerating research, expediting pharmaceutical drug development, and transforming medical standards.

View original content:https://www.prnewswire.com/apac/news-releases/histoindex-to-present-latest-findings-on-ai-based-analysis-using-stain-free-digital-pathology-with-12-accepted-abstracts-at-aasld-the-liver-meeting-2024-302298451.html

SOURCE HistoIndex

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Never Seen Underwater Imagery Honors WWII Submariners

Published

on

By

NEW YORK, Nov. 8, 2024 /PRNewswire/ — The Lost 52 Project, is honoring the memory and sacrifice of our WWII naval heroes by releasing private expedition photogrammetry footage of their submarine discoveries that span over 14 years.

The Lost 52 Project.org founded by celebrated ocean explorer and Underwater Robotics Company Founder, Tim Taylor, has unveiled never-before-seen photogrammetry footage of multiple WWII submarine discoveries, highlighting a significant milestone in the field of underwater archaeology.

The successful subsea expeditions led by the Lost 52 Project have documented the final resting sites of WWII submarines USS R-12, USS S-26, USS S-35 USS S-28, USS Grayback, USS Grunion, USS Harder and the Sumner Class Destroyer Mannert L Abele. These are underwater graves of 452 servicemen (including two Brazilian Officers) who proudly served aboard these vessels.

In recognition of their remarkable accomplishments, the Lost 52 Project has been awarded the prestigious Brazilian Navy League Medal of Honor and the project’s founder, Tim Taylor, has been honored as an honorary Brazilian submariner and conferred with the US Navy’s Distinguished Public Service Award, the highest civilian medal issued by the Navy.

The Lost 52 Project has garnered international acclaim with JAMSTEC (Japan Agency for Marine-Earth Science and Technology) hailing it as the first and most comprehensive offshore underwater archaeological expedition in the Pacific waters. The project’s recent 2023/2024 expedition was conducted in collaboration with the National Museum of the Philippines, an esteemed institution dedicated to the preservation of Filipino heritage.

Tim Taylor, CEO of Tiburon Subsea Inc. and a renowned expert in underwater robotics, expressed his enthusiasm for the project’s groundbreaking advancements in historical preservation. He states: “Through the utilization of cutting-edge 4D modeling photogrammetry technology, the Lost 52 Project has created unparalleled archaeological records that provide invaluable insights into our shared naval history.”

For more information about the groundbreaking work of the Lost 52 Project and Tim Taylor’s dedication to marine exploration, please contact Christine Dennison, Media Relations, at 212-744-6763 or via email at 386007@email4pr.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/never-seen-underwater-imagery-honors-wwii-submariners-302300290.html

SOURCE Lost 52 Project

Continue Reading

Technology

Rexton Introduces Rexton Reach inoX-CIC Li: A Rechargeable, Discreet Hearing Aid for Modern Lifestyles

Published

on

By

The durable hearing aid offers wearers an invisible, convenient solution with advanced stabilization technology that improves hearing in even the most challenging listening situations. 

ISELIN, N.J., Nov. 8, 2024 /PRNewswire/ — Expanding on its recently announced Rexton Reach hearing aid platform, hearing aid manufacturer Rexton has launched the Rexton Reach inoX-CIC Li, a rechargeable completely-in-canal (CIC) hearing aid that allows wearers to be fully involved in every conversation, even in challenging listening environments.

Rexton Reach inoX-CIC Li features an instant-fit design that fits comfortably within the ear canal, making it ideal for individuals with mild to moderate hearing loss who value both discretion and rechargeability.

Joining the Rexton Reach platform alongside the Rexton Reach R-Li T, a rechargeable receiver-in-canal (RIC) hearing aid, Rexton Reach inoX-CIC Li ensures that every voice in a conversation is clear and recognizable.

“We introduced the Rexton Reach hearing aid platform to empower wearers to fully participate in group conversations and hear multiple voices simultaneously, even amidst background noise. The Rexton Reach inoX-CIC Li expands on that mission by offering a discreet solution for wearers who may have previously rejected hearing aids due to their appearance, prioritize invisibility and want the convenience of rechargeability. For HCPs, it’s an easy-to-fit option for patients who don’t want the traditional look of receiver-in-canal hearing aids,” said Kerrie Coughlin, Vice President Brand Marketing at WSAudiology.

Rexton Reach inoX-CIC Li: An Invisible Rechargeable Hearing Aid

Rexton Reach inoX-CIC is equipped with Rexton’s voice stabilizer technology that creates differentiation between closer and farther away speakers so wearers can focus on voices they need to hear while also hearing them at the right volumes.

The hearing aids connect seamlessly with smartphones via the Rexton App, enabling users to control volume, programs, sound balance, and access remote care with ease. They feature an impressive wear time of up to 28 hours. They are fully charged in four hours via USB or wireless Qi charging, with a 30-minute fast charge adding up to six hours of runtime. They can also be charged on-the-go with a stylish charging case that holds up to four full charges.

Rexton Reach inoX-CIC Li features a robust Lifeproof® design that can withstand the drops, splashes, and scratches of everyday life and is built with rugged components that are extensively tested to ensure they can withstand whatever life throws at them. It also features an ATEX certification, which verifies that they are tested and approved to be intrinsically safe for use in potentially explosive environments.

“Rexton Reach inoX-CIC Li represents the perfect blend of discretion, performance, and convenience,” continued Coughlin. “Wearers look for hearing aids that not only help them hear better but also fit seamlessly into their lives. This new addition to our Rexton Reach platform achieves that goal. By providing a hearing aid that is both reliable and discreet, we’re empowering users to confidently participate in every aspect of their personal and professional lives.”

Rexton Reach inoX-CIC Li is available in Mocha and Black color options. It’s available at select hearing care professionals (HCPs), HearUSA centers, and Costco Hearing Centers nationwide.

For more information about Rexton Reach and its features and availability, visit www.rexton.com. For hi-res photography, click here.

About Rexton
Rexton is a global hearing aid brand established in 1955. At Rexton, we believe that nothing hearing related should ever be left to chance, both for the people with hearing loss, and those who depend upon them. We understand the challenges those with hearing loss face, and in response we offer proven hearing technology that is made Lifeproof, so it can be counted upon to perform reliably in even the most challenging of environments. At work, at home, in harsh weather or climates, you can always RELY ON REXTON.

Media Contact:
Dan Griffin
Griffin360
386059@email4pr.com
212-481-3456

View original content:https://www.prnewswire.com/news-releases/rexton-introduces-rexton-reach-inox-cic-li-a-rechargeable-discreet-hearing-aid-for-modern-lifestyles-302300289.html

SOURCE Rexton

Continue Reading

Technology

MARPAI TO HOST WEBCAST ON NOVEMBER 12, 2024 TO DISCUSS THIRD QUARTER 2024 FINANCIAL RESULTS

Published

on

By

TAMPA, Fla., Nov. 8, 2024 /PRNewswire/ — Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a technology platform company, operates as a national Third-Party Administrator (TPA) through its subsidiaries. We’re transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans. The Company will host a conference call and webcast on Tuesday, November 12 at 8:30 a.m. ET to present the Company’s operational and financial highlights for its third quarter 2024. The Company will report its third quarter results on Monday after the market close.

Event:

Marpai Third Quarter Financial Results Conference Call

Date:

November 12, 2024

Time:

8:30 a.m. Eastern Time

Call:   

US: 1-646-357-8785 / Toll Free: 1-800-836-8184

Webcast:   

https://app.webinar.net/Jd298rR8DBe

To instantly join the conference call by phone, please use the following link to easily register close to the call start time. After registering, the system will call you instantly and connect you into the conference call automatically: https://emportal.ink/4f2qTxJ

Alternatively, you may dial in to the conference call by calling 1-646-357-8785 or 1-800-836-8184 and you will be connected to the call by an Operator.

You may also stream the call by Webcast by following this link: https://app.webinar.net/Jd298rR8DBe. The webcast replay will be available at the same URL within 2 hours of the end of the call. A replay of the call will be available within 2 hours of the end of the call until November 19, 2024 by calling 1-646-517-4150 or 1-888-660-6345 and entering the replay code, 07499 #.

About Marpai, Inc.

Marpai, Inc. (OTCQX: MRAI) is a technology platform company which operates subsidiaries that provide TPA and value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Marpai works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit https://ir.marpaihealth.com the content of which is not incorporated by reference into this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/marpai-to-host-webcast-on-november-12-2024-to-discuss-third-quarter-2024-financial-results-302300301.html

SOURCE Marpai

Continue Reading

Trending